🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to scientists.

A Global Health Concern

Cases of gonorrhoea are escalating globally, with figures suggesting over 82 million instances each year. Especially elevated rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options presently on offer.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Approval

One new antibiotic, alternatively called a brand name, was approved by the American regulatory agency in December for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GSK, gained clearance in concurrent days. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to develop it.

“This milestone signifies a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Data and Worldwide Availability

Based on findings published in a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which uses two antibiotics. The trial included over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals treating patients have expressed positive views. Access to a one-pill regimen of this kind is described as a "game-changer" for gonorrhoea control. This is deemed vital to reduce the burden of the illness for people and to stop the proliferation of extremely resistant gonorrhoea globally.